RIVOPHARM SA

Based in Switzerland, RIVOPHARM SA is a pharmaceutical company that focuses on the development, manufacturing, and marketing of generic medicines, providing healthcare solutions worldwide. Founded in 1961 & led by CEO Piero Poli, RIVOPHARM SA specializes in generic pharmaceuticals and is headquartered in Manno, Switzerland. Rivopharm SA specializes in the development, manufacture, and marketing of pharmaceutical products within the generic sector, offering over 100 different molecules and more than 2000 Stock Keeping Units (SKUs) that span a wide array of therapeutic areas. The company's core product offerings include high-quality generics designed to address various health conditions, emphasizing efficacy and safety for patients.

Rivopharm's innovative technologies and highly experienced team facilitate the effective delivery of these products to healthcare providers, pharmacies, and hospitals, ensuring that end-users benefit from affordable medication options. The company actively serves a global client base, with a presence in more than 60 countries, including markets in Europe, the United Kingdom, Poland, the Baltic region, and the Nordics, thereby addressing the diverse needs of healthcare systems around the world. Rivopharm generates revenue through a structured approach that encompasses partnerships, B2B transactions, and direct sales to healthcare providers and pharmacies. The company's revenue model is primarily focused on the sale of its pharmaceutical products to a network of wholesalers and distributors, who in turn supply hospitals and pharmacies.

This B2B framework allows Rivopharm to maintain a steady flow of revenue from bulk orders and long-term contracts. While specific pricing plans for individual products are not disclosed, the revenue is anticipated to be driven by the volume of sales across its extensive product portfolio, which includes a range of niche and high-quality generics that cater to the demands of various therapeutic segments. In October 2025, Laprophan, a portfolio company of Mediterrania Capital Partners, Proparco, FMO, and DEG, acquired a 60% majority stake in RIVOPHARM SA. The acquisition enables Rivopharm SA to partner with a larger international pharmaceutical group, supporting its expansion beyond Europe and access to Laprophan’s broader geographic footprint and resources.